目的探讨在实施原发性肝癌疾病诊断期间血清肿瘤标志物+血常规指标检测联合应用可行性。方法选择该院2017年1月—2019年2月收治的52例原发性肝癌疾病患者作为研究实验组;同时间段选择52例慢性乙肝患者作为研究比照组;针对两组研究对象于临床均展开血清肿瘤标志物+血常规检测,最终就检测结果进行对比分析。结果比照组AFP水平为(21.06±3.95)μg/L,CA19-9水平为(25.63±5.22)U/mL,NLR水平为(4.25±0.99);WBC水平为(6.90±1.13)×109/L;实验组AFP水平为(35.49±4.25)μg/L,CA19-9水平为(52.39±5.29)U/mL,NLR水平为(8.07±1.03);WBC水平为(12.06±2.69)×109/L;最终发现,实验组原发性肝癌患者AFP水平、CA19-9水平、NLR水平以及WBC水平均高于比照组明显,差异有统计学意义(t=17.934 0,25.965 1,19.281 6,12.752 9,P<0.05)。结论原发性肝癌患者在接受临床疾病诊断期间,血清肿瘤标志物+血常规指标检测的有效应用,对于患者的AFP水平、CA19-9水平、NLR水平以及WBC水平可以充分明确,从而对于原发性肝癌疾病的早期诊治提供依据参考,最终对于原发性肝癌患者病情好转状态的提升,奠定基础。
Objective To investigate the feasibility of combined detection of serum tumor markers and blood routine markers during the diagnosis of primary liver cancer. Methods A total of 52 patients with primary liver cancer who were admitted to our hospital from January 2017 to February 2019 were enrolled as the study group. 52 patients with chronic hepatitis B were selected as the study comparison group. Serum tumor markers + blood routine tests were performed, and the results were compared and analyzed. Results The AFP level of the comparison group was (21.06±3.95)μg/L, the CA19-9 level was (25.63±5.22) U/mL, the NLR level was (4.25±0.99);the WBC level was (6.90±1.13)×109/L;experimental group AFP level was (35.49±4.25)μg/L, CA19-9 level was (52.39±5.29) U/mL, NLR level was (8.07±1.03);WBC level was (12.06±2.69)×109/L;Finally, the AFP level, CA19-9 level, NLR level and WBC level of the primary liver cancer patients in the experimental group were significantly higher than those in the control group (t=17.934 0, 25.996 1, 19.281 6,12.752 9,P<0.05). Conclusion The effective application of serum tumor markers + blood routine indicators during the diagnosis of patients with primary liver cancer can fully clarify the AFP level, CA19-9 level, NLR level and WBC level of patients. The early diagnosis and treatment of hepatocellular carcinoma disease provides a basis for reference, and finally lays a foundation for the improvement of the condition of patients with primary liver cancer.
World Journal of Complex Medicine
Serum tumor markers
Blood routine indicators
Primary liver cancer